A RSV Vaccine in Pregnancy Cuts Your Baby's Chance of Hospital Admission by up to 85% #pregnancy
Why It Matters
The vaccine’s high efficacy can dramatically reduce pediatric RSV hospitalizations, easing strain on healthcare systems and improving outcomes for vulnerable newborns.
Key Takeaways
- •Maternal RSV vaccine reduces infant hospitalizations by up to 85%.
- •Study analyzed nearly 300,000 births, covering 90% of England.
- •Protection strongest when infants born ≥4 weeks after maternal dose.
- •Premature infants gain significant benefit after ≥2 weeks post‑vaccination.
- •Vaccine given around week 28 of pregnancy; consult midwife.
Summary
The video reports findings from the largest real‑world evaluation of the maternal respiratory syncytial virus (RSV) vaccine in England, tracking nearly 300,000 births between September 2024 and March 2025.
Researchers found infants whose mothers received the RSV shot during pregnancy were up to 85 % less likely to be hospitalized with RSV‑related lower‑respiratory infection. The protective effect was most pronounced when babies were born at least four weeks after the maternal dose; even preterm infants showed a marked reduction when delivery occurred two weeks or more post‑vaccination.
“Babies born to vaccinated mothers had dramatically lower admission rates,” the study authors noted, highlighting the vaccine’s efficacy across term and premature populations. The analysis covered 90 % of all English births, providing robust, population‑level evidence.
These results support routine administration of the RSV vaccine at around 28 weeks gestation, offering a powerful tool to curb infant hospital burden and inform public‑health policy worldwide.
Comments
Want to join the conversation?
Loading comments...